Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Alzheimer's Association stories

Nov 17, 2026

Cognito's light-and-sound Alzheimer's headset fails pivotal trial

Cognito Therapeutics' Spectris AD device, which uses flickering light and rhythmic sound to induce gamma waves, failed to meaningfully slow Alzheimer's disease progression in its long-anticipated Phase 3 trial.

Nov 17, 2026·2 sources
00

Top claims

  • ▪Stephanie Buss, a cognitive neurologist at Beth Israel Deaconess Medical Center, stated that an approved Spectris AD device would complement rather than replace existing Alzheimer's drugs
  • ▪Eric McDade, a neurologist at Washington University School of Medicine in St. Louis, characterized the Spectris AD trial as negative and stated any next step should be a follow-up study
  • ▪Trial instructions directed participants to wear the Spectris AD headset for 50 to 60 minutes a day, at least five days a week, over 12 months

Topics

Neurodegenerative diseaseAlzheimer's diseaseAlzheimer’s & dementiaNeuroscienceFDA regulatory approvalDrug Policy, Pricing & ApprovalRandomized controlled trialClinical trials